Intrinsic fibrillation of fast-acting insulin analogs

Journal of Diabetes Science and Technology

Volumn 6, Issue 2, 2012, Pages 265-276

  Woods, R Jeremy ^a   Alarcoń, Javier ^a   McVey, Elaine ^a   Pettis, Ronald J ^a  

^a BD Technologies   (United States)

Author keywords

Amyloid; Circular dichroism; Excipients; Fibrils; Insulin; Insulin stability; Intrinsic fibrillation; Protein aggregation; Protein precipitation; Thioflavine T

Indexed keywords

AMYLOID BETA PROTEIN; BUFFER; EXCIPIENT; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; PHOSPHATE BUFFERED SALINE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; INSULIN;

AGITATION; ANALYSIS; ANALYTIC METHOD; ARTICLE; CHEMICAL STRUCTURE; DEVICES; DRUG FORMULATION; DRUG STABILITY; ELECTRON MICROSCOPY; FIBER; HEATING; PRECIPITATION; PROTEIN AGGREGATION; PROTEIN FIBRILLATION; PROTEIN STRUCTURE; THERMOGRAVIMETRY; ULTRAVIOLET RADIATION; CHEMISTRY; CIRCULAR DICHROISM; COMPARATIVE STUDY; DRUG DOSAGE FORM; HEAT; HUMAN; KINETICS; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STABILITY; SOLUBILITY; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROPHOTOMETRY;

CHEMICAL PRECIPITATION; CHEMISTRY, PHARMACEUTICAL; CIRCULAR DICHROISM; DOSAGE FORMS; DRUG STABILITY; HOT TEMPERATURE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; INSULIN LISPRO; KINETICS; MICROSCOPY, ELECTRON, TRANSMISSION; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STABILITY; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84865114967     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600209     Document Type: Article

References (69)

1. Mahler HC, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2009;98(9):2909-34.
2. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-75.
3. Weiss WF 4th, Young TM, Roberts CJ. Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci. 2009;98(4):1246-77.
4. Patel J, Kothari R, Tunga R, Ritter NM, Tunga BS. Stability considerations for biopharmaceuticals, part 1. BioProc Int. 2011;9:20-31.
5. Morozova-Roche L, Malisauskas M. A false paradise - mixed blessings in the protein universe: the amyloid as a new challenge in drug development. Curr Med Chem. 2007;14(11):1221-30. (Pubitemid 46739323)
6. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm. 2005;289(1-2):1-30. (Pubitemid 40093537)
7. Maas C, Hermeling S, Bouma B, Jiskoot W, Gebbink MF. A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem. 2007;282(4):2229-36. (Pubitemid 47076754)
8. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8(3):E501-7. (Pubitemid 44294011)
9. Chiti F, Webster P, Taddei N, Clark A, Stefani M, Ramponi G, Dobson CM. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci USA.1999;96(7):3590-4. (Pubitemid 29168954)
10. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science. 2002;296(5575):1991-5. (Pubitemid 34627514)
11. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10 Suppl:S10-7. (Pubitemid 38901862)
12. Rochet JC, Lansbury PT Jr. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol. 2000;10(1):60-8.
13. Nelson R, Sawaya MR, Balbirnie M, Madsen AØ, Riekel C, Grothe R, Eisenberg D. Structure of the cross-beta spine of amyloidlike fibrils. Nature. 2005;435(7043):773-8. (Pubitemid 40839722)
14. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA. 2002;99(26):16742-7. (Pubitemid 36034043)
15. Tycko R. Progress towards a molecular-level structural understanding of amyloid fibrils. Curr Opin Struct Biol. 2004;14(1):96-103. (Pubitemid 38249598)
16. Brange J, Andersen L, Laursen ED, Meyn G, Rasmussen E. Toward understanding insulin fibrillation. J Pharm Sci. 1997;86(5):517-25. (Pubitemid 27203397)
17. Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, Fink AL. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry. 2001;40(20):6036-46. (Pubitemid 32466306)
18. Sluzky V, Tamada JA, Klibanov AM, Langer R. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci USA. 1991;88(21):9377-81. (Pubitemid 21915634)
19. Sluzky V, Klibanov AM, Langer R. Mechanism of insulin aggregation and stabilization in agitated aqueous solutions. Biotechnol Bioeng. 1992;40(8):895-903.
20. Ahmad A, Millett IS, Doniach S, Uversky VN, Fink AL. Partially folded intermediates in insulin fibrillation. Biochemistry. 2003;42(39):11404-16. (Pubitemid 37205734)
21. Jiménez JL, Nettleton EJ, Bouchard M, Robinson CV, Dobson CM, Saibil HR. The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci USA. 2002;99(14):9196-201. (Pubitemid 34764590)
22. .Manno M, Craparo EF, Podestà A, Bulone D, Carrotta R, Martorana V, Tiana G, San Biagio PL. Kinetics of diferent processes in human insulin amyloid formation. J Mol Biol. 2007;366(1):258-74. (Pubitemid 46123327)
23. Ahmad A, Uversky VN, Hong D, Fink AL. Early events in the fibrillation of monomeric insulin. J Biol Chem. 2005;280(52):42669-75. (Pubitemid 43049225)
24. Ivanova MI, Sievers SA, Sawaya MR, Wall JS, Eisenberg D. Molecular basis for insulin fibril assembly. Proc Natl Acad Sci USA. 2009;106(45):18990-5.
25. Groenning M, Frokjaer S, Vestergaard B. Formation mechanism of insulin fibrils and structural aspects of the insulin fibrillation process. Curr Protein Pept Sci. 2009;10(5):509-28.
26. Guilhem I, Leguerrier AM, Lecordier F, Poirier JY, Maugendre D. Technical risks with subcutaneous insulin infusion. Diabetes Metab. 2006;32(3):279-84. (Pubitemid 43966754)
27. Pryce R. Diabetic ketoacidosis caused by exposure of insulin pump to heat and sunlight. BMJ. 2009;338:a2218.
28. Rahuel-Clermont S, French CA, Kaarsholm NC, Dunn MF, Chou CI. Mechanisms of stabilization of the insulin hexamer through allosteric ligand interactions. Biochemistry. 1997;36(19):5837-45. (Pubitemid 27214935)
29. Whittingham JL, Edwards DJ, Antson AA, Clarkson JM, Dodson GG. Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro - > Asp insulin analogues. Biochemistry. 1998;37(33):11516-23. (Pubitemid 28388193)
30. Derewenda U, Derewenda Z, Dodson EJ, Dodson GG, Reynolds CD, Smith GD, Sparks C, Swenson D. Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature. 1989;338(6216):594-6.
31. Bakaysa DL, Radziuk J, Havel HA, Brader ML, Li S, Dodd SW, Beals JM, Pekar AH, Brems DN. Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: Dissociation of a protein-ligand complex. Protein Sci. 1996;5(12):2521-31.
32. .Ciszak E, Beals JM, Frank BH, Baker JC, Carter ND, Smith GD. Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin. Structure. 1995;3(6):615-22.
33. Richards JP, Stickelmeyer MP, Flora DB, Chance RE, Frank BH, DeFelippis MR. Self-association properties of monomeric insulin analogs under formulation conditions. Pharm Res. 1998;15(9):1434-41. (Pubitemid 28427933)
34. .Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23(5):583-8. (Pubitemid 30321534)
35. Brange J, Vølund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev. 1999;35(2-3):307-35. (Pubitemid 29073621)
36. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174-83. (Pubitemid 40096614)
37. Becker RH. Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther. 2007;9(1):109-21.
38. Holleman F, Hoekstra JB. Insulin lispro. N Engl J Med. 1997;337(3):176-83. (Pubitemid 27306290)
39. Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharm Sci. 2008;97(8):2924-35.
40. Harrison DM, Garratt CJ. The accurate measurement of insulin molarity. Biochem J. 1969;113(4):733-4.
41. Krüger P, Gilge G, Cabuk Y, Wollmer A. Cooperativity and intermediate states in the T - R-structural transformation of insulin. Biol Chem Hoppe Seyler. 1990;371(8):669-73. (Pubitemid 20277174)
42. Teska B, Alarcon J, Pettis RJ, Randolph T, Carpenter J. Effect of phenol and m-cresol depletion on analog insulin conformational stability. AAPS J. 2011;12:S1. http://www.aapsj.org/abstracts/NBC-2011/T2077.pdf. Accessed January 12, 2012.
43. Kodali R, Wetzel R. Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol. 2007;17(1):48-57. (Pubitemid 46242190)
44. LeVine H 3rd. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods in Enzymol. 1999;309:274-84.
45. Groenning M, Norrman M, Flink JM, van de Weert M, Bukrinsky JT, Schluckebier G, Frokjaer S. Binding mode of Thioflavin T in insulin amyloid fibrils. J Struct Biol. 2007;159(3):483-97. (Pubitemid 47351257)
46. Meinhardt J, Sachse C, Hortschansky P, Grigorief N, Fändrich M. Abeta(1-40) fibril polymorphism implies diverse interaction patterns in amyloid fibrils. J Mol Biol. 2009;386(3):869-77.
47. Nelson R, Sawaya MR, Balbirnie M, Madsen A∅, Riekel C, Grothe R, Eisenberg D. Structure of the cross-beta spine of amyloidlike fibrils. Nature. 2005;435(7043):773-8.
48. Pedersen JS, Dikov D, Flink JL, Hjuler HA, Christiansen G, Otzen DE. The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. J Mol Biol. 2006;355(3):501-23. (Pubitemid 41785753)
49. Hortschansky P, Schroeckh V, Christopeit T, Zandomeneghi G, Fändrich M. The aggregation kinetics of Alzheimer's beta-amyloid peptide is controlled by stochastic nucleation. Protein Sci. 2005;14(7):1753-9. (Pubitemid 40994145)
50. .Xue WF, Homans SW, Radford SE. Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc Natl Acad Sci USA. 2008;105(26):8926-31.
51. Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem. 2001;276(14):10737-44. (Pubitemid 38089246)
52. Kusumoto Y, Lomakin A, Teplow DB, Benedek GB. Temperature dependence of amyloid beta-protein fibrillization. Proc Natl Acad Sci USA. 1998;95(21):12277-82. (Pubitemid 28483756)
53. Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. Rationalization of the efects of mutations on peptide and protein aggregation rates. Nature. 2003;424(6950):805-8. (Pubitemid 37021713)
54. .Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA. 2002;99 Suppl 4:16427-32. (Pubitemid 35470989)
55. López de la Paz M, Serrano L. Sequence determinants of amyloid fibril formation. Proc Natl Acad Sci. 2004;101(1):87-92. (Pubitemid 38084208)
56. .Andersen CB, Otzen D, Christiansen G, Rischel C. Glucagon amyloid-like fibril morphology is selected via morphology-dependent growth inhibition. Biochemistry. 2007;46(24):7314-24. (Pubitemid 46974004)
57. Bouchard M, Zurdo J, Nettleton EJ, Dobson CM, Robinson CV. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci. 2000;9(10):1960-7.
58. Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci USA. 2008;105(47):18349-54.
59. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science. 2005;307(5707):262-5. (Pubitemid 40116242)
60. Manno M, Craparo EF, Martorana V, Bulone D, San Biagio PL. Kinetics of insulin aggregation: disentanglement of amyloid fibrillation from large-size cluster formation. Biophys J. 2006;90(12):4585-91. (Pubitemid 43830902)
61. Zheng J, Liu C, Sawaya MR, Vadla B, Khan S, Woods RJ, Eisenberg D, Goux WJ, Nowick JS. Macrocyclic β-sheet peptides that inhibit the aggregation of a tau-protein-derived hexapeptide. J Am Chem Soc. 2011;133(9):3144-57.
62. Giehm L, Otzen DE. Strategies to increase the reproducibility of protein fibrillization in plate reader assays. Anal Biochem. 2010;400(2):270-81.
63. Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA. 1995;92(3):763-7.
64. .Kim YS, Randolph TW, Stevens FJ, Carpenter JF. Kinetics and energetics of assembly, nucleation, and growth of aggregates and fibrils for an amyloidogenic protein. Insights into transition states from pressure, temperature, and co-solute studies. J Biol Chem. 2002;277(30):27240-6. (Pubitemid 34951741)
65. Andersen CB, Otzen D, Christiansen G, Rischel C. Glucagon amyloid-like fibril morphology is selected via morphology-dependent growth inhibition. Biochemistry. 2007;46(24):7314-24. (Pubitemid 46974004)
66. Brange J. The new era of biotech insulin analogues. Diabetologia. 1997;40 Suppl 2:S48-53. (Pubitemid 27306922)
67. Fändrich M 2007. Absolute correlation between lag time and growth rate in the spontaneous formation of several amyloid-like aggregates and fibrils. J Mol Biol. 2007;365(5):1266-70. (Pubitemid 46048846)
68. Groenning M, Frokjaer S, Vestergaard B. Formation mechanism of insulin fibrils and structural aspects of the insulin fibrillation process. Curr Protein Pept Sci. 2009;10(5):509-28.
69. Ludwig DB, Webb JN, Fernández C, Carpenter JF, Randolph TW. Quaternary conformational stability: The efect of reversible self-association on the fibrillation of two insulin analogs. Biotechnol Bioeng. 2011. Epub ahead of print.